122 related articles for article (PubMed ID: 34190725)
1. CLINICAL FEATURES AND OUTCOMES OF INFANTS WITH RETINOPATHY OF PREMATURITY WHO FAIL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Xu LT; Levine DA; Hutchinson AK; Rao P; Hubbard GB
Retina; 2021 Nov; 41(11):2269-2277. PubMed ID: 34190725
[TBL] [Abstract][Full Text] [Related]
2. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
3. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
4. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
5. Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection.
Bhatt AR; Paul Chan RV; Reynolds JD; Wagner RS
J Pediatr Ophthalmol Strabismus; 2019 Mar; 56(2):68-70. PubMed ID: 30889257
[No Abstract] [Full Text] [Related]
6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
7. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab.
Alyamaç Sukgen E; Çömez A; Koçluk Y; Cevher S
Ophthalmologica; 2016; 236(3):139-147. PubMed ID: 27682852
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
9. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
[TBL] [Abstract][Full Text] [Related]
10. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
[TBL] [Abstract][Full Text] [Related]
11. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
13. A Surgical Technique for the Management of Tractional Retinal Detachment in Aggressive Posterior Retinopathy of Prematurity Treated With Intravitreal Bevacizumab.
De la Huerta I; Yonekawa Y; Thomas BJ; Capone A
Retina; 2019 Oct; 39 Suppl 1():S156-S159. PubMed ID: 30198966
[No Abstract] [Full Text] [Related]
14. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
[TBL] [Abstract][Full Text] [Related]
15. Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity.
Agarwal-Sinha S; Guevara JG; Amin SM
Can J Ophthalmol; 2018 Jun; 53(3):e99-e103. PubMed ID: 29784188
[No Abstract] [Full Text] [Related]
16. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
17. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
19. FLUORESCEIN ANGIOGRAPHY EVALUATION OF CHILDREN PREVIOUSLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY FOR RETINOPATHY OF PREMATURITY.
Poslu Karademir F; Vural A; Özbaş M; Demirayak B
Retina; 2024 May; 44(5):901-908. PubMed ID: 38150651
[TBL] [Abstract][Full Text] [Related]
20. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]